HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rite Aid

This article was originally published in The Rose Sheet

Executive Summary

Drug store chain Rite Aid will acquire Eckerd and Brooks drug stores in the U.S. from Canadian firm Jean Coutu in a transaction valued at $3.4 bil., retail company announces Aug. 24. The deal will add 1,521 Eckerd and 337 Brooks stores and six distribution centers to the Rite Aid chain, making the firm the largest drug store chain on the East Coast and strengthening its position as the third largest nationally with about 5,000 stores. All stores will be rebranded under the Rite Aid name. Under terms of the transaction, which was approved by the boards of directors of both firms, Jean Coutu will receive $1.45 bil. in cash and 250 mil. shares of Rite Aid stock. Rite Aid will assume $850 mil. of Jean Coutu's long-term debt. Michel Coutu, president of Jean Coutu's U.S. group, will become co-chair of Rite Aid's board. Jean Coutu acquired the Eckerd chain from J.C. Penney in April 2004 ("The Rose Sheet" April 12, 2004, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel